Disease · MONDO_0005266

diabetic retinopathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diabetic retinopathy. Diseases, record MONDO_0005266. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005266

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diabetic retinopathy; Open Targets
Open Targets ID: MONDO_0005266; Open Targets
Other names: Diabetic Retinopathies, Retinopathies, Diabetic, Retinopathy, Diabetic; Open Targets
Disease Ontology: DOID:8947; Disease Ontology
MeSH: D003930; MeSH
NCI Thesaurus: C34538; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 68 drugs, from DailyMed, EMA Human Drugs and TTD; Open Targets

Drugs68

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RANIBIZUMAB	CHEMBL1201825	Antibody	Approval	DailyMed and EMA Human Drugs	15	10	10	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	DailyMed and EMA Human Drugs	10	8	8	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
CALCIUM DOBESILATE	CHEMBL2106191	Small molecule	Approval	TTD	2	1	1	Drugs and targets
CAPTOPRIL	CHEMBL1560	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
FENOFIBRATE	CHEMBL672	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
AXITINIB	CHEMBL1289926	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METFORMIN	CHEMBL1431	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
OCTREOTIDE	CHEMBL1680	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 68

See all 68 drugs

Targets107

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS2	Cyclooxygenase	5	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
VEGFA	Vascular endothelial growth factor A, long form	5	Vascular endothelial growth factor A inhibitor	Approval	https://conductscience.org/library/genes/7422	Drugs and targets
NR3C1	Glucocorticoid receptor	4	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	4	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5742	Drugs and targets
ACE	Angiotensin-converting enzyme	2	Angiotensin-converting enzyme inhibitor	Approval	https://conductscience.org/library/genes/1636	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
IL2RA	Interleukin-2 receptor	2	Interleukin-2 receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3559	Drugs and targets
IL2RB	Interleukin-2 receptor	2	Interleukin-2 receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3560	Drugs and targets
IL2RG	Interleukin-2 receptor	2	Interleukin-2 receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3561	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets

1 to 10 of 107

See all 107 targets

Trials71

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00252720	DIabetic Retinopathy Candesartan Trials.	Phase 3	1,850	2014-06-03	Type 1 Diabetes	CANDESARTAN	Its record names the disease	ClinicalTrials.gov
NCT00604383	Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study	Phase 3	685	2016-01-28	Diabetic Retinopathy	RUBOXISTAURIN	Its record names the disease	ClinicalTrials.gov
NCT05409235	Nesvategrast (OTT166) in Diabetic Retinopathy (DR)	Phase 2	225	2024-08-09	Diabetic Retinopathy	NESVATEGRAST ISOBUTANOLAMMONIUM	Its record names the disease	ClinicalTrials.gov
NCT04503551	A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm	Phase 3	174	2025-11-25	Diabetic Retinopathy	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04265261	A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy	Phase 2	139	2024-09-25	Diabetic Retinopathy	VICASINABIN	Its record names the disease	ClinicalTrials.gov
NCT04722991	Non-proliferative Diabetic Retinopathy Treated With Runcaciguat	Phase 2	109	2025-04-08	Diabetic Retinopathy	RUNCACIGUAT	Its record names the disease	ClinicalTrials.gov
NCT02299336	Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial	Phase 4	60	2018-06-07	Diabetic Macular Edema	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT01292798	Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab	Phase 1/2	43	2016-04-22	Diabetic Macular Edema	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00511875	Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy	Phase 2	30	2018-11-02	Diabetic Retinopathy	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT01441102	Dextromethorphan for Diabetic Macular Edema	Phase 1/2	7	2015-06-08	Diabetic Macular Edema	DEXTROMETHORPHAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 71

See all 71 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Candesartan vs Placebo: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale	127 of 951	124 of 954	1,905	NCT00252720	Trial comparisons
Candesartan vs Placebo: Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).	110 of 951	107 of 954	1,905	NCT00252720	Trial comparisons
Candesartan vs Placebo: Number of Participants With a Regression of Diabetic Retinopathy.	140 of 951	139 of 954	1,905	NCT00252720	Trial comparisons
Candesartan vs Placebo: serious adverse events	173 of 951	161 of 951	1,902	NCT00252720	Trial comparisons
Ruboxistaurin vs Placebo: serious adverse events	145 of 345	157 of 340	685	NCT00604383	Trial comparisons
Runcacigat (BAY1101042) vs Placebo: Number of Participants With Treatment Emergent Adverse Event (TEAE)	53 of 56	44 of 53	109	NCT04722991	Trial comparisons
Runcaciguat (BAY1101042) vs Placebo: deaths from any cause	2 of 56	0 of 53	109	NCT04722991	Trial comparisons
Runcaciguat (BAY1101042) vs Placebo: serious adverse events	9 of 56	3 of 53	109	NCT04722991	Trial comparisons
Doxycycline Monohydrate vs Placebo: serious adverse events	3 of 15	3 of 15	30	NCT00511875	Trial comparisons

Papers from its trials39

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
30584490	RESULT	1	PubMed
21813293	RESULT	1	PubMed
20970870	RESULT	1	PubMed
20082624	RESULT	1	PubMed
19064853	RESULT	1	PubMed
17896294	RESULT	1	PubMed
16681561	RESULT	1	PubMed
15078674	RESULT	1	PubMed
11522720	RESULT	1	PubMed
10857967	RESULT	1	PubMed

1 to 10 of 39

See all 39 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005266

GET https://conductscience.org/api/diseases/v1/MONDO_0005266/drugs?page=2

API reference For AI assistants